Christopher R. Richied
Profile
Christopher R.
Richied served as the Chief Executive Officer at EnzyMed, Inc. and as the Chief Financial Officer & Vice President at AmpliMed Corp.
and Cancer Prevention Pharmaceuticals, Inc. He obtained an undergraduate degree from The Ohio State University, a graduate degree from the University of Arizona, and an MBA from Harvard Business School.
Former positions of Christopher R. Richied
| Companies | Position | End |
|---|---|---|
EnzyMed, Inc.
 EnzyMed, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Curia Global, Inc., EnzyMed, Inc. is a company that specializes in the discovery, optimization, and derivatization of pharmaceutical and agrochemical lead compounds. The company is based in Coralville, IA. The company was founded by J. Wesley Fox Ahmann. EnzyMed was acquired by Curia Global, Inc. on October 20, 1999 for $20.60 million. | Director of Finance/CFO | 2010-03-25 |
| CANCER PREVENTION PHARMACEUTICALS INC | Director of Finance/CFO | - |
AmpliMed Corp.
 AmpliMed Corp. Pharmaceuticals: MajorHealth Technology AmpliMed Corp. develops and manufactures drugs to treat cancer. Its products include amplimexon, amplizone and benzimidazole series. The firm is focused on the development of small-molecule oncology drugs with novel mechanisms of action. The company was founded by Evan M. Hersh, David S. Alberts, Robert Thomas Dorr and William A. Remers in 1989 and is headquartered in Tucson, AZ. | Director of Finance/CFO | - |
Training of Christopher R. Richied
| The Ohio State University | Undergraduate Degree |
| University of Arizona | Graduate Degree |
| Harvard Business School | Masters Business Admin |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
AmpliMed Corp.
AmpliMed Corp. Pharmaceuticals: MajorHealth Technology AmpliMed Corp. develops and manufactures drugs to treat cancer. Its products include amplimexon, amplizone and benzimidazole series. The firm is focused on the development of small-molecule oncology drugs with novel mechanisms of action. The company was founded by Evan M. Hersh, David S. Alberts, Robert Thomas Dorr and William A. Remers in 1989 and is headquartered in Tucson, AZ. | Health Technology |
Cancer Prevention Pharmaceuticals, Inc.
 Cancer Prevention Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cancer Prevention Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of therapeutic agents for the treatment and prevention of certain pre-cancerous conditions, orphan diseases and gastrointestinal conditions. The company’s pipeline consists of Gastrointestinal and Orphan. Cancer Prevention Pharmaceuticals was founded by Dr. Frank Meyskens and Gene Gerner in June 9, 2008 and is headquartered in Tucson, AZ. | Health Technology |
EnzyMed, Inc.
EnzyMed, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Curia Global, Inc., EnzyMed, Inc. is a company that specializes in the discovery, optimization, and derivatization of pharmaceutical and agrochemical lead compounds. The company is based in Coralville, IA. The company was founded by J. Wesley Fox Ahmann. EnzyMed was acquired by Curia Global, Inc. on October 20, 1999 for $20.60 million. | Commercial Services |
- Stock Market
- Insiders
- Christopher R. Richied
